- Home
- ANNX vs INNV Comparison
ANNX vs INNV Comparison
Compare ANNX & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- INNV
- Stock Information
- Founded
- ANNX 2011
- INNV 2007
- Country
- ANNX United States
- INNV United States
- Employees
- ANNX N/A
- INNV N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- INNV Medical/Nursing Services
- Sector
- ANNX Health Care
- INNV Health Care
- Exchange
- ANNX Nasdaq
- INNV Nasdaq
- Market Cap
- ANNX 362.4M
- INNV 373.3M
- IPO Year
- ANNX 2020
- INNV 2021
- Fundamental
- Price
- ANNX $1.60
- INNV $3.64
- Analyst Decision
- ANNX Strong Buy
- INNV Sell
- Analyst Count
- ANNX 5
- INNV 2
- Target Price
- ANNX $18.67
- INNV $5.00
- AVG Volume (30 Days)
- ANNX 1.6M
- INNV 36.1K
- Earning Date
- ANNX 05-20-2025
- INNV 05-06-2025
- Dividend Yield
- ANNX N/A
- INNV N/A
- EPS Growth
- ANNX N/A
- INNV N/A
- EPS
- ANNX N/A
- INNV N/A
- Revenue
- ANNX N/A
- INNV $831,683,000.00
- Revenue This Year
- ANNX N/A
- INNV $13.21
- Revenue Next Year
- ANNX N/A
- INNV $10.29
- P/E Ratio
- ANNX N/A
- INNV N/A
- Revenue Growth
- ANNX N/A
- INNV 12.19
- 52 Week Low
- ANNX $1.29
- INNV $2.60
- 52 Week High
- ANNX $7.85
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- ANNX 38.84
- INNV 66.17
- Support Level
- ANNX $1.62
- INNV $2.84
- Resistance Level
- ANNX $2.01
- INNV $3.18
- Average True Range (ATR)
- ANNX 0.13
- INNV 0.26
- MACD
- ANNX 0.01
- INNV 0.08
- Stochastic Oscillator
- ANNX 0.00
- INNV 98.95
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.